CervoMed provided an update on its Phase 2b RewinD-LB trial for neflamapimod in dementia with Lewy bodies (DLB). The blinded portion of the trial showed no significant difference between neflamapimod and placebo, likely due to lower-than-expected drug concentrations potentially linked to the age of the drug batch used. However, subsequent analyses and a food-effect study suggest newer capsules achieve the targeted plasma concentrations.
This development is crucial because DLB is a prevalent neurodegenerative disease with limited treatment options. Confirming the efficacy of neflamapimod at the correct dosage could represent a significant advancement in addressing a substantial unmet medical need, potentially improving the quality of life for hundreds of thousands of patients. Furthermore, a successful therapy could significantly impact healthcare costs associated with DLB, which are currently higher than those for Alzheimer’s diseaseAlzheimer’s disease.
Technically, the initial results of the RewinD-LB trial were disappointing due to low drug concentrations. However, the investigation into this issue identified the older drug batch as a likely culprit. Data from the open-label extension phase, using a newer batch, is expected to provide more definitive results on the drug’s efficacy at the targeted plasma concentrations. This data is anticipated in the first quarter of 2025.
The upcoming data readout from the open-label extension phase of RewinD-LB is critical for the future of neflamapimod. If the newer capsules demonstrate efficacy, it will validate the drug’s potential and justify further clinical development. Positive results could pave the way for a Phase 3 trial and eventual regulatory approval, offering a much-needed treatment option for DLB patients. Conversely, if the results remain lackluster, CervoMed will need to reassess its development strategy for neflamapimod in DLB.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
